

Devyser raises €1,6M in funding to launch new NGS-products for cancer diagnostics

Stockholm, Sweden, December 15, 2015 — Devyser (www.devyser.com) has raised €1,6M (\$1,8M) in funding to support the launch of new cancer diagnostic products in 2016. Funds were raised from current shareholders and a development loan from the Swedish regional development agency ALMI.

The first product scheduled for release allows complete sequencing of the BRCA1 and BRCA2 genes to help guide treatment of patients with breast and ovarian cancers carrying BRCA-mutations.

“NGS technology has the capacity to revolutionize genetic testing, but uptake has been hindered by labor-intensive and complex workflows up until now” says Ulf Klangby, CEO and co-founder of Devyser. “We are excited to introduce a pioneering NGS product suited for routine diagnostics. Fast to implement and easy to use, Devyser’s proprietary technology reduces the hands-on time from days to hours, allowing laboratories to significantly improve efficiency and cut costs.”

Other Devyser products scheduled for launch in 2016 include additional cancer diagnostic products and a genetic test for complete sequencing of the CFTR gene used in the diagnosis of Cystic Fibrosis.

Contact:

Ulf Klangby, CEO Devyser, ulf.klangby@devyser.com, +46 733 709 298

About Devyser AB

Devyser is specialised in the development, manufacturing and sales of in-vitro diagnostics products for genetic testing. The company was founded in Stockholm in 2005 and has introduced more than 20 products to genetic laboratories worldwide. The products are used to guide targeted cancer therapies, for rapid prenatal diagnostics, genetic testing and reproductive health. Devyser’s products enable higher speed, accuracy and cost-effectiveness in diagnostic services. www.devyser.com.